- Home
- TOL vs MRNA Comparison
TOL vs MRNA Comparison
Compare TOL & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOL
- MRNA
- Stock Information
- Founded
- TOL 1967
- MRNA 2010
- Country
- TOL United States
- MRNA United States
- Employees
- TOL N/A
- MRNA N/A
- Industry
- TOL Homebuilding
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TOL Consumer Discretionary
- MRNA Health Care
- Exchange
- TOL Nasdaq
- MRNA Nasdaq
- Market Cap
- TOL 14.8B
- MRNA 16.0B
- IPO Year
- TOL N/A
- MRNA 2018
- Fundamental
- Price
- TOL $135.13
- MRNA $34.06
- Analyst Decision
- TOL Buy
- MRNA Hold
- Analyst Count
- TOL 15
- MRNA 20
- Target Price
- TOL $153.67
- MRNA $76.35
- AVG Volume (30 Days)
- TOL 1.5M
- MRNA 10.7M
- Earning Date
- TOL 02-18-2025
- MRNA 02-20-2025
- Dividend Yield
- TOL 0.68%
- MRNA N/A
- EPS Growth
- TOL 21.44
- MRNA N/A
- EPS
- TOL 15.01
- MRNA N/A
- Revenue
- TOL $10,846,740,000.00
- MRNA $5,081,000,000.00
- Revenue This Year
- TOL $2.05
- MRNA N/A
- Revenue Next Year
- TOL $7.21
- MRNA N/A
- P/E Ratio
- TOL $9.00
- MRNA N/A
- Revenue Growth
- TOL 8.52
- MRNA N/A
- 52 Week Low
- TOL $95.46
- MRNA $31.94
- 52 Week High
- TOL $169.52
- MRNA $170.47
- Technical
- Relative Strength Index (RSI)
- TOL 53.40
- MRNA 34.88
- Support Level
- TOL $131.81
- MRNA $33.34
- Resistance Level
- TOL $137.51
- MRNA $35.68
- Average True Range (ATR)
- TOL 3.19
- MRNA 2.46
- MACD
- TOL 2.09
- MRNA -0.75
- Stochastic Oscillator
- TOL 84.08
- MRNA 12.49
About TOL Toll Brothers Inc.
Toll Brothers is the leading luxury homebuilder in the United States with an average sale price well above public competitors'. The company operates in over 60 markets across 24 states and caters to move-up, active-adult, and second-home buyers. Traditional homebuilding operations represent most of company's revenue. Toll Brothers also builds luxury for-sale and for-rent properties in urban centers across the US It has its headquarters in Horsham, Pennsylvania.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.